TLP Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

TLP Group’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-113	Closed	-$7K	–	670
2017 Q4	$7K	Buy	+113	New	+$7.13K	﹤0.01%	420
2017 Q3	–	Sell	-2,051	Closed	-$248K	–	643
2017 Q2	$248K	Sell	2,051 -1,305	-39%	-$151K	0.23%	145
2017 Q1	$380K	Buy	+3,356	New	+$392K	0.26%	99

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

TLP Group's ICPT Position: Q1 2018 in Review

TLP Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2018, closing a stake of 113 shares — an estimated $7K sold.

TLP Group first reported a position in ICPT in Q1 2017 and held it in 3 quarters. The position peaked at $380K in Q1 2017. 147 funds tracked by Wall St. Rank hold ICPT as of Q1 2018.

TLP Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
TLP Group sold 113 Intercept Pharmaceuticals, Inc. shares in Q1 2018, an estimated $7K.
TLP Group first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2017 and held it in 3 quarters.
TLP Group's Intercept Pharmaceuticals, Inc. position peaked at $380K in Q1 2017.
147 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2018.

Based on TLP Group's 13F filing for Q1 2018, filed 16 May 2018.